NPPA revised retail price of 1 new formulation: February 2025

Last Updated on March 7, 2025 by The Health Master

NPPA

Download NPPA notification No. S.O. 661 (E) dt 07-02-2025, the link is given below: The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 1 new formulation under the Drugs (Prices Control) Order, 2013, vide S.O. 661(E) dt 07-02-2025 based on the decision of 129th Authority meeting dated 29-01-2025.

The notification states as follows:

In implementation of directions of review order issued by the Department of Pharmaceuticals (DOP) under para 31 of Drugs (Prices Control) Order, 2013 vide order specified in column (7) of the table below and in exercise of the powers conferred by paragraphs 5,11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. and date specified in the Column (7) of the table, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (5) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (8) thereof;

A table is given below the article

Note:

(a) The manufacturer as specified in column (8), of the above mentioned formulations i.e. “new drug” under paragraph 2(1)(u) of the DPCO, 2013 may revise the retail price as specified in column (5) of the table hereinabove.

(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (5) of the above said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any Person wishing to consult the same.

(e) The above mentioned retail prices are applicable only to the manufacturer / marketer as mentioned above for generic / any brand of the same composition / strength of the subject formulations, subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (8) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (8) thereof, if any, issued prior to this notification, stand(s) superseded.

Table

S. No.	Name of the Formulation	Dosage form & Strength	Unit	Retail Price (Rs.)	DoP Review no. & Date	Existing SO number & date	Manufacturer & Marketing Company respectively
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
1.	Cilnidipine & Telmisartan Tablets	Each film coated tablet contains: Cilnidipine IP 20mg Telmisartan IP 40mg	1 Tablet	14.15	31015/60/2023- Pricing dated 04.10.2024	1434(E) dated 27.03.2023 (at Sl. No.22)	M/s Akums Drugs & Pharmaceuticals Ltd. M/s Glenmark Pharmaceuticals Limited

• IP 2026 released: Salient Features
  January 7, 2026
• Drug alert: 205 drug samples declared as NSQ in November 2025
  December 25, 2025
• FDA Haryana is Redefining Drug Safety and MSMEs Growth
  December 17, 2025
• 10th edition of IP for standards of drugs in India
  December 9, 2025
• QR Code mandatory at every Medical Store for ADR reporting
  November 26, 2025
• Landmark Seminar by FDA Haryana on Spurious drugs and NDPS Misuse
  November 25, 2025